About Contact Us Careers

Hypertension Drugs Market Size and Forecast, by Drug Class (Alpha & Beta Blockers, Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Renin Inhibitors); Type (Systemic, Pulmonary); Distribution Channel (Hospitals, Clinics, Research Laboratories, Retail Pharmacies) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 2845
  • Published Date: Sep 08, 2025
  • Report Format: PDF, PPT

Hypertension Drugs Market Outlook:

Hypertension Drugs Market size was valued at USD 27.8 billion in 2025 and is likely to cross USD 39.98 billion by 2035, expanding at more than 3.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of hypertension drugs is estimated at USD 28.73 billion.

Hypertension Drugs Market size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The market is expanding due to an increase in hypertension cases around the world, as it is a condition caused by chronic kidney infection, apnea, and other factors, and is the most common health disorder among the majority of the global population. As a result, the high demand for hypertension drugs is attributed to the high sales volume of hypertension drugs and their available treatment options.

The growing prevalence of insomnia across the globe is believed to fuel market growth. For instance, insomnia is a common sleep disorder that makes it difficult to fall asleep or sometimes causes a person to wake up early. Insomnia is noticed to be interlinked with hypertension and beta-blockers are highly used to treat insomnia heavily across the globe. For instance, it was stated that in every 3 adults across the globe, one of them has insomnia.

Key Hypertension Drugs Market Insights Summary:

  • Regional Highlights:

    • North America hypertension drugs market is poised to capture 30% share by 2035, driven by the presence of key market players developing innovative hypertension drugs.
    • Asia Pacific market will secure the second largest share by 2035, driven by the rising geriatric population and increased need for long-term care.

  • Segment Insights:

    • The diuretics segment in the hypertension drugs market is expected to maintain a 48% share by 2035, supported by its cost-effectiveness and wide preference in hypertension treatment.
    • The systemic segment in the hypertension drugs market is forecasted to achieve a significant share by 2035, attributed to the prevalence of systemic hypertension requiring targeted treatments.

  • Key Growth Trends:

    • Increasing Prevalence of Renal Disease
    • Rising Trend of Work from Home (WFH)

  • Major Challenges:

    • Rising Number of Alternate Generic Drugs
    • Possibilities of Side-Effect such as Dizziness and Headaches

  • Key Players: Janssen Global Services, LLC, Atnahs Pharma UK Limited, Sanofi US Services Inc., Pfizer Laboratories Div Pfizer Inc, Merck & Co., Inc., Abbott Laboratories, Daiichi Sankyo Company, Limited, Novartis Pharmaceuticals Corporation, Boehringer Ingelheim group, Lupin Ltd.

Global Hypertension Drugs Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 27.8 billion
    • 2026 Market Size: USD 28.73 billion
    • Projected Market Size: USD 39.98 billion by 2035
    • Growth Forecasts: 3.7% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (30% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Japan, Germany, United Kingdom
    • Emerging Countries: China, India, Japan, South Korea, Singapore

    • Last updated on : 8 September, 2025

Growth Drivers

  • Increasing Prevalence of Renal Disease- renal disease is a medical condition in which kidneys are damaged and lose their capability to filter blood causing severe health problems such as hypertension is one of them. For instance, around 800 million people across the globe are observed to be living with some sort of renal disease.
  • Rising Trend of Work from Home (WFH) – work from home is a process that involves less mobility that can cause strain in arteries carrying blood. Hence, working from home is noticed to be one of the major reasons. Around 80% of the employees were observed to prefer working from home while by the year 2025, around 35 million Americans will be working remotely.
  • Growing Consumption of Tobacco and Cigarette- smoking habits and tobacco consumption can be one of the major causes of hypertension since it was noticed to increase blood pressure and masked hypertension. For instance, it was estimated that around 8 million people die annually owing to the consumption of tobacco.

Challenges

  • Rising Number of Alternate Generic Drugs- There is an increase in the number of generic drugs and other substitutes associated with the treatment of hypertension which negatively affects the market growth. Further, the presence of some side effects of these drugs is estimated to hinder the growth of the global hypertension drugs market during the forecast period.
  • Possibilities of Side-Effect such as Dizziness and Headaches
  • Higher Cost Associated with Hypertension Drugs

Hypertension Drugs Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

3.7%

Base Year Market Size (2025)

USD 27.8 billion

Forecast Year Market Size (2035)

USD 39.98 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Hypertension Drugs Market Segmentation:

Drug Class Segment Analysis     

The diuretics segment is estimated to gain a robust market share of 48% in the coming years owing to its high preference among the majority of patients for hypertension treatment. Diuretics, sometimes known as water pills, help the body get rid of surplus fluids and are frequently tried as the first drug for hypertension.  They are preferred by patients owing to their effectiveness, inexpensive price, and few adverse effects. For instance, Chlorthalidone is one of the most often prescribed thiazide diuretics, which has been FDA-approved since 1960. Further, studies have shown that 1 in every 3 adults having hypertension was reported to take diuretics, which is anticipated to drive the growth of the diuretics segment during the forecast period.

Type  Segment Analysis     

The pulmonary segment in the hypertension drugs market is set to garner a notable share in the near future. Pulmonary hypertension is described as high blood pressure in the blood vessels that are responsible for supplying blood to pulmonary arteries. Pulmonary disease can be life-threatening since it can damage the right side of the heart. For instance, around 500 to 100 new cases of pulmonary arterial hypertension are diagnosed in the United States every year which sums up to nearly 12 cases per million people.

Furthermore, the systemic segment is also anticipated to hold a significant share of the hypertension drug market during the forecast period. Systemic hypertension is also another form of high blood pressure in arteries carrying blood from the heart to the body.

Our in-depth analysis of the global market includes the following segments:

           Drug Class
  • Alpha & Beta Blockers
  • Diuretics
  • Angiotensin Converting Enzyme Inhibitors
  • Angiotensin II Receptor Blockers
  • Renin Inhibitors

           Type
  • Systemic
  • Pulmonary

            Distribution Channel
  • Hospitals
  • Clinics
  • Research Laboratories
  • Retail Pharmacies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Hypertension Drugs Market Regional Analysis:

North American Market Insights

Hypertension drugs market in North America is predicted to account for the largest share of 30% by 2035, impelled by the presence of leading market players in the region that manufacture and market hypertension drugs. For instance, the presence of leading market players may result in the development of innovative drugs for hypertension and improved treatment options for patients in the region.

APAC Market Statistics Insights

The APAC hypertension drugs market is estimated to be the second largest, during the forecast timeframe led by the rise in the geriatric population, especially in countries such as China, India, and Japan. The elderly population is more prone to chronic conditions such as high blood pressure which requires long-term management. This extended treatment period is expected to increase the demand for hypertension drugs in the region. According to the World Health Organization (WHO), owing to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040.

Hypertension Drugs Market shares
Get Strategic Analysis by Region Now: Request Free Sample PDF

Hypertension Drugs Market Players:

    • Janssen Global Services, LLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Atnahs Pharma UK Limited
    • Sanofi US Services Inc.
    • Pfizer Laboratories Div Pfizer Inc
    • Merck & Co., Inc.
    • Abbott Laboratories
    • Daiichi Sankyo Company, Limited
    • Novartis Pharmaceuticals Corporation
    • Boehringer Ingelheim group
    • Lupin Ltd.

Recent Developments

  • Janssen Global Services, LLC announced that it has submitted an approval request to the U.S. Food and Drug Administration (FDA) for OPSUMIT (macitentan) for treating adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4)
  • AstraZeneca announced that it has completed the divestment agreement of its established hypertension medicines with Atnahs Pharma UK Limited.
  • Report ID: 2845
  • Published Date: Sep 08, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of hypertension drugs is estimated at USD 28.73 billion.

The global hypertension drugs market size was around USD 27.8 billion in 2025 and is likely to expand at a CAGR of more than 3.7%, surpassing USD 39.98 billion revenue by 2035.

North America hypertension drugs market is poised to capture 30% share by 2035, driven by the presence of key market players developing innovative hypertension drugs.

Key players in the market include Janssen Global Services, LLC, Atnahs Pharma UK Limited, Sanofi US Services Inc., Pfizer Laboratories Div Pfizer Inc, Merck & Co., Inc., Abbott Laboratories, Daiichi Sankyo Company, Limited, Novartis Pharmaceuticals Corporation, Boehringer Ingelheim group, Lupin Ltd.

Hypertension Drugs Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos